Search research articles
Contact Us
Filters
Showing results (61-70 of 110) with videos related to
Page
of 11
Sort By:
Social Science & Medicine (1982)
|
July 14, 2023
Health care provider decision-making and the quality of maternity care: An analysis of postpartum care in Kenyan hospitals
Dan Han, Emma Clarke-Deelder, Nora Miller, et al.
Current Medical Research and Opinion
|
January 17, 2019
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Ralph P Insinga, David J Vanness, Josephine L Feliciano, et al.
American Journal of Public Health
|
September 12, 2014
Community socioeconomic disadvantage and the survival of infants with congenital heart defects
James E Kucik, Wendy N Nembhard, Pamela Donohue, et al.
Trends in Molecular Medicine
|
September 10, 2014
The current epidemiology and clinical decisions surrounding acute respiratory infections
Aimee K Zaas, Bronwen H Garner, Ephraim L Tsalik, et al.
Cancer Medicine
|
August 2, 2025
Patient-Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017-2021
Loretta A Williams, Cai Xu, Darcy A Ponce, et al.
Immunotherapy
|
March 15, 2024
Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer
Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, et al.
The Biochemical Journal
|
April 25, 2003
Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence
Angie F Kirwan, Ashley C Bibby, Thierry Mvilongo, et al.
Pharmacoeconomics
|
December 6, 2018
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer
Min Huang, M Catherine Pietanza, Ayman Samkari, et al.
Immunotherapy
|
November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
Min Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.
Journal of Environmental Health
|
September 7, 2007
Enhancing the Maryland environmental public health workforce: a collaborative approach
Beth Resnick, Joanna Zablotsky, Olivia Farrow, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 110) with videos related to
Sort By:
Page
of 11
Social Science & Medicine (1982)
|
July 14, 2023
Health care provider decision-making and the quality of maternity care: An analysis of postpartum care in Kenyan hospitals
Dan Han, Emma Clarke-Deelder, Nora Miller, et al.
Current Medical Research and Opinion
|
January 17, 2019
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Ralph P Insinga, David J Vanness, Josephine L Feliciano, et al.
American Journal of Public Health
|
September 12, 2014
Community socioeconomic disadvantage and the survival of infants with congenital heart defects
James E Kucik, Wendy N Nembhard, Pamela Donohue, et al.
Trends in Molecular Medicine
|
September 10, 2014
The current epidemiology and clinical decisions surrounding acute respiratory infections
Aimee K Zaas, Bronwen H Garner, Ephraim L Tsalik, et al.
Cancer Medicine
|
August 2, 2025
Patient-Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017-2021
Loretta A Williams, Cai Xu, Darcy A Ponce, et al.
Immunotherapy
|
March 15, 2024
Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer
Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, et al.
The Biochemical Journal
|
April 25, 2003
Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence
Angie F Kirwan, Ashley C Bibby, Thierry Mvilongo, et al.
Pharmacoeconomics
|
December 6, 2018
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer
Min Huang, M Catherine Pietanza, Ayman Samkari, et al.
Immunotherapy
|
November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
Min Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.
Journal of Environmental Health
|
September 7, 2007
Enhancing the Maryland environmental public health workforce: a collaborative approach
Beth Resnick, Joanna Zablotsky, Olivia Farrow, et al.
Page
of 11